Best Defensive Companies To Watch In Right Now

At Tier 1 Investments, I seek out and invest in elite businesses. These include companies with the most valuable brands, best management, superior products and services, and strongest competitive advantages.

You may have heard your friends refer to Whole Foods (NASDAQ: WFM  ) as "whole paycheck," in reference to its high prices. Whether that's a bad rap or not, perceptions can damage a brand. But can the grocery stalwart clear out this bruised fruit without getting into a defensive price-war?

It's hard to believe that a grocery store could book investors more than 30 times their initial investment, but that's just what Whole Foods has done for those who saw the organic trend coming some 20 years ago. However, it may not be too late to participate in the long-term growth of this organic foods powerhouse. In this brand-new premium report on the company, we walk through the key must-know items for every Whole Foods investor, including the main opportunities and threats facing the company. So make sure to claim your copy today by clicking here.

Hot High Dividend Companies To Buy Right Now: Fifth Street Finance Corp (FSC)

Fifth Street Finance Corp. is a specialty finance company that lends to and invests in small and mid-sized companies in connection with investments by private equity sponsors. The Company�� investment objective is to maximize its portfolio's total return by generating current income from its debt investments and capital appreciation from its equity investments. As of September 30, 2011, 90.9% of its portfolio consisted of debt investments that were secured by first or second priority liens on the assets of its portfolio companies. As of September 30, 2011, it held equity investments consisting of common stock, preferred stock or other equity interests in 27 out of 65 portfolio companies. It is managed and advised by Fifth Street Management LLC. In June 2013, Fifth Street Finance Corp. announced that it has closed its portfolio company acquisition of Healthcare Finance Group, LLC (HFG).

Investments

The Company tailors the terms of its debt investments to the facts and circumstances of the transaction and prospective portfolio company. As of September 30, 2011, it directly originated a majority of its debt investments. It is focusing its origination efforts on first lien, second lien and subordinated loans. Its first lien loans have terms of four to six years, provide for a variable or fixed interest rate, contain prepayment penalties and are secured by a first priority security interest in all existing and future assets of the borrower. Its first lien loans may take many forms, including revolving lines of credit, term loans and acquisition lines of credit. Its second lien loans have terms of four to six years, provide for a fixed interest rate, contain prepayment penalties and are secured by a second priority security interest in all existing and future assets of the borrower. Its second lien loans often include payment-in-kind (PIK), interest, which represents contractual interest accrued and added to the principal that generally becomes due at maturity. Its unsecured inve! stments have terms of five to six years and provide for a fixed interest rate. It may make unsecured investments on a stand-alone basis, or in connection with a senior secured loan, a junior secured loan or a one-stop financing. Its unsecured investments may include payment-in-kind (PIK), interest, which represents contractual interest accrued and added to the principal that becomes due at maturity, and an equity component, such as warrants to purchase common stock in the portfolio company.

In addition, the Company from time to time non-control, equity co-investments in connection with private equity sponsors. It structures equity investments, such as direct equity co-investments, to provide the Company with minority rights provisions and event-driven put rights. The Company make investments in the private equity funds of certain of its equity sponsors. It makes these investments where it has a long term relationship and is comfortable with the sponsor�� business model and investment strategy. As of September 30, 2011, it had investments in six private equity funds, which represented less than 1% of the fair value of its assets as of such date.

Portfolio Management

As a business development company, the Company offers managerial assistance to its portfolio companies and to provide it if requested. It monitors the financial trends of each portfolio company to assess the appropriate course of action for each company and to evaluate overall portfolio quality. It has several methods of evaluating and monitoring the performance of its investments, which includes review of monthly and quarterly financial statements and financial projections for portfolio companies; periodic and regular contact with portfolio company management; attendance at board meetings; periodic formal update interviews with portfolio company management, and assessment of business development, including product development, profitability and the portfolio company�� overall adherence to its busine! ss plan.

In addition to various risk management and monitoring tools, the Company uses an investment rating system to characterize and monitor the credit profile and expected level of returns on each investment in itd portfolio. It uses a five-level numeric rating scale. In the event that it determines that an investment is underperforming, or circumstances suggest that the risk associated with a particular investment has significantly increased, it monitors the effected portfolio company.

Valuation of Portfolio Investments

As a business development company, the Company invests in illiquid securities, including debt and equity investments of small and mid-sized companies. The Company perform valuations of its debt and equity investments on an individual basis, using market, income, and bond yield approaches as appropriate. Under the market approach, it estimates the enterprise value of the portfolio companies, in which it invests. To estimate the enterprise value of a portfolio company, it analyze various factors, including the portfolio company�� historical and projected financial results. It requires portfolio companies to provide annual audited and quarterly and monthly unaudited financial statements, as well as annual projections for the upcoming fiscal year.

Under the income approach, the Company prepares and analyze discounted cash flow models based on projections of the future free cash flows of the business. Under the bond yield approach, it uses bond yield models to determine the present value of the future cash flow streams of its debt investments. It reviews various sources of transactional data, including private mergers and acquisitions involving debt investments with similar characteristics, and assess the information in the valuation process.

Advisors' Opinion:

• [By Bryan Perry] Popular Posts: Trade of the Day: Groupon (GRPN)Lloyds (LYG): A Sweet Stock Across the PondDoes Fifth Street Finance (FSC) Deserve a Spot in Your Portfolio? Recent Posts: Does Fifth Street Finance (FSC) Deserve a Spot in Your Portfolio? Trade of the Day: Groupon (GRPN) Trade of the Day: U.S. Steel (X) View All Posts

  If you’re holding Fifth Street Finance (FSC), criticism that it’s not covering its dividend with net investment income and is not projected to do so in 2014 might have you second-guessing its place in your lineup.

Best Defensive Companies To Watch In Right Now: Anacor Pharmaceuticals Inc. (ANAC)

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company�s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company�s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

Advisors' Opinion:

• [By Roberto Pedone]

   

  Anacor Pharmaceuticals (ANAC), a biopharmaceutical company, focuses on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. This stock closed up 6.6% to $16.90 in Monday's trading session.

   

  Monday's Volume: 2.22 million
  
  Three-Month Average Volume: 425,667
  
  Volume % Change: 412%

   

  From a technical perspective, ANAC gapped sharply higher here back above both its 50-day moving average of $15.97 and its 200-day moving average of $16.50 with monster upside volume. This stock recently formed a double bottom chart pattern at $14.95 to $15.11. Since tagging that bottom, shares of ANAC have started to rip higher and move within range of triggering a big breakout trade. That trade will hit if ANAC manages to take out Monday's intraday high of $17.03 to $17.62 and then once it clears more near-term overhead resistance at $18.73 with high volume.

   

  Traders should now look for long-biased trades in ANAC as long as it's trending above Monday's intraday low of $16.15 and then once it sustains a move or close above those breakout levels with volume that hits near or above 425,667 shares. If that breakout kicks off soon, then ANAC will set up to re-test or possibly take out its next major overhead resistance levels at $21.27 to $23.07.

   

Best Defensive Companies To Watch In Right Now: First Trust Exchange Traded Fund (FVL)

First Trust Value Line 100 Fund (the Fund) is a diversified closed-end management investment company. The Fund seeks to outperform the Standard & Poor's 500 Composite Stock Price Index (the S&P 500 Index) by adhering to a strategy of investing in a diversified portfolio of the 100 common stocks ranked number 1 in Value Line's Timeliness Ranking System. The Fund invests 80% of its net assets in the stocks that are ranked number one in the Value Line Timeliness Ranking System. As of March 31, 2006, the Fund had invested in sectors, such as household durables, metals and mining, specialty retail, oil and gas, software, machinery, hotels, restaurants and leisure, computers and peripherals, biotechnology, information technology services, and textiles, apparel and luxury goods.

As of March 31, 2006, the Fund's top 10 holdings were Palm, Inc., United INDL Corp., AAR Corp., Accenture LTD, Citrix Systems, Inc., Cymer Inc., Guess, Inc., Henry Jack & Assoc., Inc., Micrel Inc. and Molecular Devices Corp. The Fund had a large capitalization orientation to its portfolio holdings as of December 31, 2005. As of December 31, 2005, the 100 stocks in the portfolio consisted of large-cap stocks (34), mid-cap stocks (35) and small-cap stocks (31). During the year ended December 31, 2005, the Fund posted a net asset value (NAV) total return of 11.9% and a market value total return of 7.5%. This compared to a gain of 4.8% for the S&P 500 Index. The Fund's investment advisor is First Trust Advisors, L.P.

Advisors' Opinion:

• [By David Trainer]

  First Trust Value Line 100 ETF (FVL) is in the Danger Zone this week. FVL is another example of a supposedly "passive" ETF that purportedly tracks an index but actually resembles an actively managed portfolio. FVL's methodology tracks an index, but it is an index in name only.

Best Defensive Companies To Watch In Right Now: Alterra Capital Holdings Ltd(ALTE)

Alterra Capital Holdings Limited, together with its subsidiaries, provides specialty insurance and reinsurance products to corporations, public entities, and property and casualty insurers in North America, Europe, and internationally. It offers professional liability products, which include errors and omissions insurance, employment practices liability insurance, and directors and officers insurance; excess liability products, such as excess umbrella liability insurance, excess product liability insurance, excess medical malpractice insurance, and excess product recall insurance; and property insurance, as well as provides airline, general aviation, and aerospace insurance. The company also offers reinsurance products consisting of agriculture, auto, aviation, credit/surety, general casualty, marine and energy, medical malpractice, professional liability, property, whole account, and workers? compensation reinsurance. In addition, it offers general liability, inland mari ne, and ocean marine insurance; accident and health insurance and reinsurance, financial institutions insurance, and surety reinsurance; and employers? and public liability insurance, and medical malpractice insurance, as well as life and annuity reinsurance. The company was formerly known as Max Capital Group Ltd. and changed its name to Alterra Capital Holdings Limited in May 2010. Alterra Capital Holdings Limited was founded in 1999 and is headquartered in Hamilton, Bermuda.

Advisors' Opinion:

• [By Steve Symington]

  About that whale...
  If that weren't enough, Markel also announced this morning it has officially completed its $3 billion acquisition of Alterra (NASDAQ: ALTE  ) , which, as I noted back in February, was a radical departure from Markel's typically smaller buyout targets. While it will undoubtedly take some time to fully integrate Alterra's operations, management expressed excitement for Alterra's ability to help Markel expand its global footprint in the insurance and reinsurance market.

Best Defensive Companies To Watch In Right Now: Aceto Corporation(ACET)

Aceto Corporation engages in the sourcing, regulatory support, marketing, and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals worldwide. The company operates in three segments: Health Sciences, Specialty Chemicals, and Agricultural Protection Products. The Health Sciences segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. The Specialty Chemicals segment provides various chemicals used in plastics, surface coatings, textiles, fuels, and lubricants; organic intermediates used in the production of agrochemicals; and dye and pigment intermediates used in the color-producing industries, such as textiles, inks, paper, and coatings. This segment also offers diazos and couplers to the paper, film, and electronics industries. The Agricultural Protection Products segment sells herbicides, fungicides, insecticides, and other agricultural chemicals that control weed growth, as well as control the spread of insects and other microorganisms that can damage plant growth. This segment also provides sprout inhibitor for potatoes and an herbicide for sugar cane. It serves pharmaceutical, nutraceutical, agricultural, coatings, and industrial chemical consuming industries. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.

Advisors' Opinion:

• [By Monica Gerson]

  Aceto (NASDAQ: ACET) is projected to post its Q4 earnings at $0.17 per share on revenue of $134.23 million.

  SeaChange International (NASDAQ: SEAC) is estimated to post a Q2 loss at $0.18 per share on revenue of $26.80 million.

• [By Louis Navellier]

  Portfolio Grader has noted the strong fundamentals and upgraded HII stock to an “A” last month, making it a strong buy consideration at current prices.

  Aceto (ACET)

  Aceto (ACET) sources and sells the ingredients for pharmaceutical products. ACET operates in three divisions:

Best Defensive Companies To Watch In Right Now: Triple-S Management Corporation (GTS)

Triple-S Management Corporation, through its subsidiaries, offers a portfolio of managed care and related products in the commercial and Medicare markets in Puerto Rico. The company operates in three segments: Managed Care, Life Insurance, and Property and Casualty Insurance. It provides managed care products, including health maintenance organization plans; preferred provider organization plans; Medicare Supplement products; Medicare Advantage products; Medicaid plans; and Medicare Part D, a prescription drug plan; and claims processing and other administrative services. The company offers its managed care products to employers, professional and trade associations, individuals, and government entities. It also provides various life, accident, disability, and health and annuity insurance products to individuals; and property and casualty insurance products, which include commercial multi-peril, commercial property mono-line, auto physical damage, auto liability, and dwelli ng policies to commercial customers. The company markets its products through a network of internal sales force, direct mail, independent brokers and agents, telemarketing staff, and the Internet. Triple-S Management Corporation was incorporated in 1997 and is based in San Juan, Puerto Rico.

Advisors' Opinion:

• [By Brian Pacampara]

  What: Shares of Puerto Rican managed-care company Triple-S Management (NYSE: GTS  ) popped 11% today after its quarterly results topped Wall Street expectations.